Eli Lilly will likely draw investor focus on Monday as the company said its investigational once-weekly insulin efsitora alfa ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

In a first, Eli Lilly to connect patients to telehealth providers of Alzheimer’s care The move by Lilly, which sells a treatment for the condition, is part of a direct-to-consumer push that has ...

Eli Lilly and Co. on Thursday announced the expansion of its digital health care platform, LillyDirect, to include connections to in-person and telehealth care for patients with Alzheimer’s disease.

Why should Eli Lilly care? As I alluded to above, Lilly's Mounjaro and Zepbound are dual agonists for GLP-1 and GIP-1 receptors. However, ...

Teladoc Health partners with Eli Lilly’s LillyDirect to streamline Zepbound access for weight care program members via direct home delivery. The collaboration enhances medication fulfillment ...

Purdue partnered with Eli Lilly and Company for the ninth annual Lilly Day at Purdue on Aug. 28. The daylong event took place at Memorial Mall and Stewart Center. Students had the opportunity to have ...

(Reuters) -Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.

“We are thrilled to host Lilly Day at Purdue, celebrating our robust partnership with Eli Lilly and Company. This collaboration enhances our students’ learning experience and opens doors to exciting ...

(Reuters) -Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies. The ...